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Abstract
Background: The ubiquitin(Ub)-proteasome pathway is implicated in the regulation of a variety of cellular
functions and plays a major role in stress response in eukaryotic cells, by targeting misfolded and damaged
proteins for degradation. In addition, in the presence of DNA damage, the Ub-proteasome system regulates
proteins involved in sensing, repairing, and/or tolerating the damage. Antitumor agents such as cisplatin can
activate the pathway, but the role of specific pathway components in cell sensitivity/response to the drug is not
known. Since platinum compounds represent clinically relevant antitumor agents and a major limitation to their
use is the development of drug resistance, there is an urgent need for identifying targets for improving their
efficacy.
Results: In the present study, we performed a genome-wide screening for sensitivity to cisplatin using non-
essential haploid deletion mutants of the fission yeast Schizosaccharomyces pombe, belonging to a collection of
haploid strains constructed through homologous recombination. Using this approach, we identified three Ub-
proteasome mutants exhibiting hypersensitivity to cisplatin (ubp16, ubc13 and pmt3) and ten mutants (including
ufd2, beta7 20S, rpt6/let1) resistant to the drug. In addition, the importance of lub1 gene emerged from the
comparison between the present screening and gene expression profile data previously obtained in fission yeast.
Conclusions: The factors identified in the present study allowed us to highlight most finely the close relationship
between the Ub-proteasome system and DNA damage response mechanisms, thus establishing a comprehensive
framework of regulators likely relevant also in higher eukaryotes. Our results provide the proof of principle of the
involvement of specific genes modulated by cisplatin treatment in cell response to the drug, suggesting their
potential role as targets for modulating cisplatin sensitivity. In this regard, the prospective identification of novel
targets for modulation of cisplatin sensitivity in an eukaryotic model organism appears particularly intriguing
towards the discovery of strategies to overcome cisplatin resistance in human tumors.
Background
Cisplatin (cis-diammine-dichloroplatinum) is an effective
antitumor agent widely used for the treatment of different
tumor types [1]. In spite of the efficacy, the curative poten-
tial of such an antitumor drug is limited by the occurrence
of resistance [2]. Most information about genetic alterations
and cellular mechanisms contributing to drug response/
resistance comes from mammalian cell systems [1]. Several
mechanisms of resistance to cisplatin have been described
including reduced drug accumulation, enhanced repair and
increased expression of defence factors [2,3]. Some lines of
evidence support the concept that altered expression of sub-
sets of genes may be important in determining the sensitiv-
ity/resistance to antitumor agents including cisplatin [3].
Given the powerful molecular tools now available, the com-
bination of molecular pharmacology and molecular biology
approaches in studying model organisms could lead to a
rapid progress in the discovery of strategies to overcome
drug resistance. The ease by which yeast can be manipulated
together with similarities of yeast cells to cells of more com-
plex metazoans makes many yeast species, (e.g., the fission
yeast Schizosaccharomyces pombe) very attractive models
for the investigation of conserved evolutionary processes
occurring in eukaryotes [4]. Using DNA microarrays, we
* Correspondence: paola.perego@istitutotumori.mi.it
1Fondazione IRCCS, Istituto Nazionale per lo Studio e la Cura dei Tumori,
20133 Milan, Italy
Full list of author information is available at the end of the article
Gatti et al. BMC Genomics 2011, 12:44
http://www.biomedcentral.com/1471-2164/12/44
© 2011 Gatti et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.previously found that in fission yeast cisplatin activates a
stress response involving various gene groups [3]. In particu-
lar, among the transcripts up-regulated by cisplatin in the
sensitive strain, several genes belonging to the ubiquitin
(Ub)-proteasome pathway were identified [3].
The Ub-proteasome pathway is implicated in the regula-
tion of a variety of cellular functions and plays a major
role in stress response. In fact, by degrading misfolded and
damaged proteins, the pathway controls processes includ-
ing cell cycle, cell death and DNA repair [5,6]. The protea-
some recognizes ubiquitinated substrates through its Ub
receptors and digest them into peptides and free Ubs. The
pathway includes Ub activating enzymes (E1), Ub conju-
gating enzymes (E2) and Ub ligases (E3), all acting in con-
cert to tag substrates with Ub chains. Proteins may be
monoubiquitinated or the Ub monomer may act as a
point of attachment for additional Ub monomers, result-
ing in polyubiquitination. The specific biological signal
mediated by a polyubiquitin chain is determined, in part,
by the chain topology, which is assigned by the Ub lysine
residue used for chain extension. Lys48-linked chains have
been implicated in targeting proteins for proteasomal
degradation, whereas Lys63-linked chains seem to regulate
proteins involved in a wide range of processes, including
DNA repair, mRNA translation and endocytosis. Indeed,
the Ub-proteasome system is known to regulate the tran-
scription of many genes via both proteolytic and non-
proteolytic activities [7]. Ub modification of proteins is
reversible as Ub may be removed from proteins by de-
ubiquitinating enzymes which hydrolyze the isopeptide bond
between Ub and the substrate proteins, or by Ub proteases
which remove Ub monomers from a polyubiquitin chain.
S i n c ec o n c l u s i v ef i n d i n g sa b o u tt h es p e c i f i cc o n t r i b u -
tion of different pathways to cisplatin response in fission
yeast have been limited by the analysis of small sets of
mutants, in the present study we used a large panel of
strains to clarify the contribution of single proteasome
genes to cisplatin response. In particular, we employed
non-essential haploid deletion mutants, belonging to a
collection of haploid strains - constructed through
homologous recombination in S. pombe [8] - to examine
sensitivity to cisplatin. Here, we describe our results
aimed at clarifying the involvement of specific genes
modulated by cisplatin treatment in cell response to the
drug. Understanding the relevant genetic/biochemical
alterations of the cisplatin response pathway may pro-
vide a rational basis for improving therapy in resistant
tumors.
Results and Discussion
Experimental model
A set of mutants from a genome-wide library containing
2539 haploid strains was used in the present study. The
library represents around 70% of non-essential S. pombe
genes (25% of the genes are considered essential) and
around 2% of them belong to the Ub-proteasome path-
way (see additional file 1: Figure S1). Using terms from
the Gene Ontology (GO) Consortium, each mutant can
be assigned at least to one GO annotation (Table 1). The
GO project - The Gene Ontology http://geneontology.
org - is a major collaborative bioinformatics initiative
that aims at standardizing the representation of gene and
gene product attributes across species. Fission yeast has
at least one GO annotation for 98.3% of its known and
predicted protein coding genes (corresponding to 5031
genes, as reported in the most recent update -22/02/2010
-o fThe S. pombe Genome Project http://www.sanger.
ac.uk/Projects), greater than the current percentage cov-
erage for any other organism [9,10]. The GO terms that
are most enriched for Ub-proteasome genes are reported
in Table 1. They represent approximately 3% of gene pro-
ducts annotated to “biological processes” for fission yeast.
See additional file 2: Figure S2 and additional file 3: Fig-
ure S3, for tree views from GO.
The screening of the library was performed in liquid
c u l t u r ea s s a y s ,b e c a u s et h i st e s ti sm o r es u i t a b l et h a n
tests on plates to examine the effect of cisplatin, which
by virtue of its chemical features (i.e., electrophilicity)
easily reacts with the abundant nucleophilic components
of yeast extract plates (e.g., organic sulphur: methionine,
cysteine), thereby becoming inactive. In preliminary
experiments, the optimal drug concentrations to employ
in the deletion mutant screening were determined using
the wild-type 972 h
- and mutant rad3 strain because
rad3 is hypersensitive to cisplatin (IC50 =0 . 0 1±
0.009 μM) and 972 h
- is the strain from which rad3
mutant was generated.
Sensitivity of S. pombe deletion mutants to cisplatin
When assaying the cisplatin sensitivity of 47 deletion
mutants belonging to the proteasome pathway, we identified
Table 1 Gene Ontology analysis for ubiquitin-dependent
processes
Annotated gene
products
Name GO terms S. pombe All
organisms
All gene products All 5230 463.707
Biological processes GO:0008150 5219 349,949
Ub-dependent protein
catabolic processes
GO:0006511 177 2393
Proteasomal-Ub dependent
protein catabolic processes
GO:0043161 110 733
Protein ubiquitination GO:0016567 124 1865
Protein modification by small
protein conjugation or
removal
GO:0070467 162 1734
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in comparison to the corresponding wild-type strains
(Table 2). A list of the S. cerevisiae and human homologous/
horthologous genes corresponding to those evaluated for
cisplatin sensitivity is reported in Table 3. In particular,
we found that 3 deletion mutants were cisplatin-sensitive
(ubp16, ubc13 and pmt3) and that 10 mutants were
cisplatin-resistant (Figure 1).
Cisplatin-sensitive deletion mutants
Ubp16 (SPCC1682.12c), similar to S. cerevisiae UBP10
(YNL186W), is a Ub-specific processing protease
endowed with Ub-C-terminal hydrolase activity, and is
localized to the nucleolus of S. pombe. The correspond-
ing budding yeast homolog gene UBP10 encodes a deu-
biquitinating enzyme whose loss of function results in a
complex phenotype displaying perturbations in different
cellular processes, characterized by slow growth rate,
partial impairment of silencing at telomeres, reduced
subtelomeric repression and up-regulation of stress-
responsive genes. This complex phenotype is also
accompanied by accumulation of reactive oxygen species
and by appearance of apoptosis-like phenotypical mar-
kers [11]. UBP10 is directly involved in the maintenance
of histone H2B ubiquitination levels, that is critical for
the transcriptional and cell cycle response to DNA
damage [12]. Such observations are particularly interest-
ing since the major epigenetic mechanisms controlling
histone modifications and nucleosome remodelling are
extremely well conserved between yeast and higher
organisms [13]. Consequently, UBP10 inactivation
induced a transcriptional oxidative stress response
accompanied by a subpopulation of apoptotic cells
which accumulated reactive oxygen species [14,15]. The
corresponding human homolog gene has not been yet
described. Although significant progress has been made
in the characterization of enzymes that ligate Ub to tar-
get proteins in humans, little is known about the
removal of Ub from Ub-conjugates. Yet, the activity of
Ub-specific proteases (USPs) is likely to be central to
the regulation of all processes in which Ub is involved,
both removing Ub to rescue from degradation or by
removing residual Ub to assist in proteasomal degrada-
tion. The human genome encodes 60-70 predicted
members of the USP family, and at least five major
classes have been identified, one of which gathers
Ub-processing proteases (UBP) including UBP10. Col-
lectively, several findings identify USPs as important reg-
ulators of biological processes and potential targets for
the treatment of human tumors [16-19].
Ubc13 (SPAC11E3.04c), is a Ub-conjugating enzyme
(E2), involved in protein ubiquitination, DNA repair,
DNA post-replication repair (PRR) and in targeting of
Lys63 histone, similarly to the S. cerevisiae homolog
gene YDR092W (UBC13). In fission yeast, deletion of
Ubc13 results in an increased sensitivity to DNA dama-
ging agents, i.e., the alkyating agent methylmethanesul-
fonate (MMS) and UV radiation [20]. Since the
ubiquitination of PCNA plays a crucial role in regulating
replication past DNA damage, this aspect was investi-
gated also in S. pombe [21]. In particular, it has been
shown that the genetic requirements for mono- and
polyubiquitination of PCNA are similar to those in S.
cerevisiae, namely that monoubiquitination requires
Rhp18
Rad18, whereas polyubiquitination requires
Rad8
Rad5, Ubc13 and Mms2 [21]. DNA PRR is a toler-
ance mechanism that allows cells to survive DNA
damage that is unrepaired or unrepairable. PRR includes
translesion DNA synthesis that is “error-prone” and a
second activity that is largely “error-free”. In budding
yeast, the UBC13 gene codes for an Ub-conjugating
enzyme involved in the error-free DNA PRR pathway.
After DNA damage, Ubc13p interacts with Mms2p to
assemble Ub chains at the Ub-Lys63 residue of PCNA,
instead of the conventional Lys48 residue that is the
main signal to target a substrate for proteolysis by 26S
proteasome. The involvement of UBC13 in cellular tol-
erance to DNA damage is further supported by its indu-
cibility in response to treatment with DNA-damaging
agents such as MMS and UV radiation [22,23]. The
human homolog of S. pombe Ubc13, is UBE2N/UBC13,
a Ub-conjugating enzyme requiring the presence of a
Ubc variant (Uev) for poly-ubiquitination. In particular,
divergent activities of mammalian Ubc13 rely on its
pairing with either of two Uevs, Uev1A or Mms2
[24,25].
Pmt3 (SPBC365.06) gene product is SUMO (small,
ubiquitin-like modifier), one of a number of Ub-like
protein that are post-translationally covalently attached
to one or more Lys residues on target proteins.
Although it has only 18% sequence identity with Ub, its
structure resembles that of Ub. However, unlike Ub,
mammalian SUMO and its budding yeast homologue
SMT3 have been shown to be more important for post-
translational protein modification than for protein
degradation [26]. Indeed, SUMO modification has a
variety of cellular functions, including roles in transcrip-
tion, DNA damage response, cell cycle and nuclear
transport. Recently, Pmt3 has been shown to be
required for SUMO-targeted Ub ligase-dependent ubi-
quitination of target proteins [27]. As an example,
S. pombe PCNA is sumoylated in S phase following
DNA damage [21]. The process of sumoylation resem-
bles that of ubiquitination. SUMO is produced as a pre-
cursor protein that needs to be cleaved to the mature
form by one or more specific SUMO-proteases. Genetic
analyses showed that the pmt3 gene is not essential for
viability (while SUMO is essential for viability in
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Page 3 of 11Table 2 Cisplatin sensitivity of Ub-proteasome pathway deletion mutants
Gene ID Annotation IC50 (mM) ± SD Cisplatin response
Mutant strains
a
SPAC26A3.16 dph1 0.068 ± 0.023
SPAC328.06 ubp2 0.079 ± 0.06
SPAC24H6.03 pcu3 0.053 ± 0.006
SPAC167.07c cul3 0.048 ± 0.03
SPAC12B10.01c UB-lig (E3) 0.133 ± 0.06 R
SPBC6B1.06c ucp2, ubp14 0.08 ± 0.02
SPCC1682.12c ubp16 0.0098 ± 0.0002 HS
SPBP8B7.21 ubp3 0.11 ± 0.08
SPBC19C7.02 ubr1 0.153 ± 0.01 R
SPBP8B7.27 mug30 0.149 ± 0.001 R
SPCC1442.07c UB metalloprotease 0.061 ± 0.006
SPAC27F1.03c uch1 0.066 ± 0.018
SPAC31G5.18c UB family... 0.025 ± 0.05
SPCC188.08c ubp22/ubp15 0.065 ± 0.011
SPAC11E3.04c ubc13/spu13 0.0175 ± 0.01 HS
SPAC10F6.07c ubc6 0.062 ± 0.011
SPAC1250.03 ubc14 0.069 ± 0.012
SPAC13A11.04c ubp8 0.044 ± 0.003
SPBC800.12c UB family... 0.057 ± 0.006
SPBC106.16 pre6 0.053 ± 0.01
SPBC409.06 uch2 0.052 ± 0.02
SPBC530.03c bag102/bag1-b 0.193 ± 0.023 R
SPBC16G5.03 UB-lig (E3) 0.051 ± 0.013
SPBC19G7.09 ulp1(SUMO-deconj) 0.054 ± 0.016
SPCC1919.15 brl1 0.052 ± 0.019
SPBC2A9.04c UB-lig (E3) 0.196 ± 0.005 R
SPBC577.10 20S (sub.b7) 0.170 ± 0.011 R
SPAC17G8.10c dma1 0.063 ± 0.004
SPAC6G10.11c ubi3 0.188 ± 0.004 R
SPAC20H4.10 ufd2 0.17 ± 0.0006 R
SPBC19C2.04c ubp11 0.171 ± 0.006 R
SPBC15C4.06c UB-lig (E3) 0.055 ± 0.006
SPAC23G3.08c ubp7 0.06 ± 0.004
SPBC23G7.12c let1/rpt6 (19S) 0.18 ± 0.007 R
SPBC887.04c lub1 0.054 ± 0.005
SPAC15A10.11 ubr11 0.062 ± 0.019
SPAC1198.09 ubc16 0.032 ± 0.013
SPAC17C9.13c cut8 0.028 ± 0.002
SPBC18H10.08c ubp4 0.054 ± 0.019
SPCC790.02 pep3 0.024 ± 0.003
SPBC16E9.11c pub3 0.059 ± 0.005
SPAC1805.15c pub2 0.062 ± 0.005
SPCC1682.16 rpt4 0.03 ± 0.02
Wild-type strain
a
ED668: h
+ ade6-M216/ura4-D18/leul-32 0.09 ± 0.01
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the checkpoint coupling mitosis to the completion of
DNA replication and the DNA damage response. Dele-
tion mutants for pmt3 were strikingly sensitive to the
DNA synthesis inhibitor hydroxyurea (HU), MMS and
UV radiation, and the microtubule-destabilizing agent
thiabendazole. However, it has been proposed that pmt3
is involved in the DNA damage tolerance process rather
than in the checkpoint itself, similarly to rad31 (SUMO
activator subunit) and hus5 (SUMO conjugator) [26]. In
fission yeast, sumoylation is involved also in chromo-
some segregation and telomere length maintenance.
Loss of pmt3 function caused a striking increase in telo-
mere length [26]. More recently, a role for SUMO chain
formation in response to replication arrest in S. pombe
has been established [27]. In addition, a variable pattern
of response to DNA damaging agents has been reported
in the budding yeast SIZ1 gene mutant, which is charac-
terized by resistance to anthracyclines (doxorubicin,
daunorubicin) and sensitivity to cisplatin and camp-
tothecin [28]. Since SIZ1 is an E3-ligase of the SUMO
pathway, sumoylation defects may impair drug response.
Cisplatin-resistant deletion mutants
Although we were mainly interested in identifying drug-
sensitive mutants with the final goal to establish novel
targets for increasing cisplatin sensitivity, the present
study allowed us to identify several cisplatin-resistant
strains (Figure 1). Among these, here we describe those
carrying deletions in genes whose human homolog/
ortholog has been already described (Figure 1).
Ufd2 belongs to the Ub-conjugation factor “E4 family”
and is involved in N-terminal Ub-fusion degradation
(UFD) pathway, required for the degradation of oligo-
ubiquitinated substrates [29]. Notably, UFD2 has a cru-
cial activity in S. cerevisiae because it binds proteins
modified by one or two moieties only, thus harbouring a
too short chain for triggering degradation, and is able to
catalyze an extension of the multi-Ub chain [30,31].
A two-step reaction, i.e., oligo-ubiquitination followed
by E4-catalyzed multi-ubiquitination, could offer a dou-
ble layer of control, giving the possibility for two conse-
cutive functions [31]. Moreover, UFD2 may have a role
in retro-translocation and endoplasmic reticulum-
associated degradation (ERAD) pathway, where mis-
folded or abnormally assembled proteins are targeted
for degradation. Importantly, the bulk of UFD2 appears
to reside in the nucleus, possibly with bound ubiquiti-
nated substrates (e.g., transcription factors). The mam-
malian homolog of yeast Ufd2/UFD2 is UFD2a/UBE4B
gene, that contains a U-box at its C-terminus and func-
t i o n sa sa nE 3a sw e l la sa nE 4U b - l i g a s e[ 3 0 ] .I th a s
been demonstrated that UFD2a mediates the proteaso-
mal turnover of p73 in a Ub-independent manner and
that it might play an important role in the regulation of
cisplatin-induced apoptosis mediated by p73 [32]. More
recently, it has been suggested that UFD2a might regu-
late also cisplatin-mediated cell death by p63 [33].
T h eS P B C 5 7 7 . 1 0g e n ec o d e sf o rt h eb7s u b u n i to f
20S proteasome, whose corresponding ortholog gene in
S. cerevisiae is PRE4. A mutant strain with defects in
PRE4 displays cycloheximide resistance [34]. The corre-
sponding human gene/protein (PSMB4) is evolutionarily
conserved and directly interacts with SNEV (senescence
evasion factor), a protein with E3 ligase activity, which
is also involved in DNA double-strand break repair and
splicing, whose deficiency results in apoptosis and
decreased cell survival after DNA damage [34,35]. It has
been suggested that PSMB4 might be a major site for
proteasome regulation, where signals from the outside
might be transduced inside to the protease activities
[34]. Altered expression of the PSMB4 gene was recently
Table 2 Cisplatin sensitivity of Ub-proteasome pathway deletion mutants (Continued)
Mutant strains
a
SPAC6G9.08 ubp6 0.052 ± 0.008
SPBC6B1.05c atg7 0.073 ± 0.009
SPBC2D10.20 ubc1 0.055 ± 0.015
SPBC365.06 pmt3 0.0096 ± 0.003 HS
Wild-type strain
a
ED666: h
+ ade6-M210/ura4-D18/leul-32 0.045 ± 0.02
Cisplatin sensitive strain
a
SPBC216.05 rad3 0.01 ± 0.009
a Sensitivity was evaluated using a microtiter growth inhibition assay with a 48 h drug exposure. IC50 values are the means ± standard deviation of at least three
independent experiments. The IC50 was defined as the drug concentration that reduced the absorbance to 50% of the value measured for the untreated control
culture, and was compared to cisplatin sensitivity of the corresponding wild-type parental strain. Hypersensitive strains are indicated as HS and resistant strains
as R.
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(glioblastoma, ovarian carcinoma, hepatocarcinoma,
prostate carcinoma) through different approaches
[36-39]. Interestingly, another human gene coding for
the 20S proteasome unit b-type 7 (PSMB7), is associated
with anthracycline resistance and is a prognostic bio-
marker in breast cancer [40].
Rpt6/Let1 is one of six ATPases of the 19S regulatory
particle of the 26S proteasome involved in the degrada-
tion of ubiquitinated substrates; its S. cerevisiae homolog
gene (Rpt6p) is bound by Ub-protein ligases Ubr1p and
Ufd4p and localized mainly to the nucleus throughout
the cell cycle. The Rpt6 protein (also known as Sug1 in
budding yeast and hSug1/TRIP1/S8/PSMC5 in mam-
mals) has been found to associate with a number of
activators and to be localized on some promoters in
mammals [41]. In particular, Rpt6 has been localized on
p21
WAF1 promoter where it interacts with p53 after
DNA damage. The knockdown of Rpt6 results in
increased occupancy of the p21
WAF1 promoter by p53
and increase transcription of the gene [41].
Modulation of Ub-proteasome genes by cisplatin
We previously studied genome-wide transcriptional pro-
files in S. pombe, demonstrating that cisplatin activates a
stress response involving genes belonging to different
pathways (glutathione, heat-shock, DNA repair), includ-
ing Ub-proteasome system) [3]. In such an analysis, the
S. pombe wild-type sensitive strain 972 h
- was exposed
to a cytotoxic cisplatin concentration and modulation of
gene expression was examined. The group of transcripts
at least two-fold up-regulated by cisplatin in this strain
Table 3 Ub-proteasome pathway deletion mutants
evaluated for cisplatin sensitivity: S. cerevisiae and
human homolog/ortholog genes
Homolog/Ortholog
Annotation S. cerevisiae Human
dph1 DSK2 -
ubp2 UBP2 -
pcu3 - -
cul3 UFD4 -
UB-lig (E3) - -
ucp2, ubp14 UBP14 -
ubp16 UBP10 -
ubp3 YER151C -
ubr1 UBR1/PTR1/UBR2 -
mug30 HUL4 -
UB-metalloprotease - -
uch1 YUH1 UCHL3
UB family... - -
ubp22/ubp15 UPB15 USP7
ubc13/spu13 UBC13 UBC13/UBE2N
ubc6 UBC6 UBE2J2
ubc14 - -
ubp8 UBP8 USP22
Ub family... - -
pre6 PRE6 PSMA8
uch2 YUH1 UCHL3
bag102 / bag1-b SNL1 -
UB-lig (E3) - -
ulp1 (SUMO-deconj) ULP1 SENP8
brl1 BRE1 -
UB-lig (E3) SAN1 -
20S (sub.b7) PRE4 PSMB4
dma1 DMA1 -
ubi3 RPS31 -
ufd2 UFD2 UBE4B
ubp11 - -
UB-lig (E3) - -
ubp7 UBP7 USP45
let1/rpt6 (19S) RPT6 PSMC5
lub1 DOA1 PLAA
ubr11 - UBR2
ubc16 - -
cut8 - -
ubp4 DOA4/UBP4 -
pep3 - VPS18
pub3 RSP5 NEDD4
pub2 RSP5 NEDD4
rpt4 RPT4 PSMC6
ubp6 UBP6 USP14
atg7 ATG7 ATG7
ubc1 UBC1 UBE2K
pmt3 SMT3 SUMO
Figure 1 Sensitivity of S. pombe deletion mutants to cisplatin.
In the bar-chart are reported three cisplatin-sensitive and ten
cisplatin-resistant strains with the corresponding human homolog/
ortholog genes, when described. IC50 values are the means ±
standard deviation of at least three independent experiments. WT,
wild-type strains (ED 668: h
+ ade6-M216/ura4-D18/leu1-32 and
ED666: h
+ ade6-M210/ura4-D18/leu1-32, respectively).
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Ub-proteasome pathway (Table 4). Only three of them
w e r ef o u n dt ob ei n c l u d e di nt h ep r e s e n ts e to fn o n -
essential deletion mutants (Lub1, Ubc6 and Uch2). When
we tested cisplatin sensitivity of these specific deletion
mutants (see Table 2), we obtained IC50 values similar to
that of the corresponding wild-type parental strain.
Among the induced transcripts, Lub1 attracted our
attention because a precise and important role in DNA
damage response has been recently ascribed to its corre-
sponding budding yeast homolog gene, DOA1/UFD3
[12]. In particular, DOA1 has been shown to help to
control the DNA damage response by channelling Ub
from the proteasomal degradation pathway into path-
ways that mediate altered DNA replication and chroma-
tin modification, thus acting in supplying Ub for the
DNA damage response. Elements of the DNA damage
response that appear to rely on DOA1 include the ubi-
quitination of both PCNA and histone H2B. Indeed,
DOA1 interacts with other factors involved in producing
or maintaining ubiquitinated both PCNA and H2B, i.e.,
UBC13 and UBP10 (the S. cerevisiae homolog of fission
yeast Ubc13 and Ubp16, see above for details). Thus,
such an observation suggests a link between three differ-
ent factors belonging to the Ub-proteasome pathway
identified in S. pombe with two different approaches
(global gene expression analysis and cell sensitivity
screening), and possibly involved in cellular response to
cisplatin. Moreover, the lack of cisplatin-hypersensitivity
observed in our Lub1 deletion mutant (see Table 2),
may reflect the presence of redundant factors as sug-
gested by Lis and Romesberg [12]. Indeed, in budding
yeast doa1Δ and ubi4Δ mutants share several pheno-
types including sensitivity to heat, canavanine and other
DNA-damaging agents (HU, MMS) [42]. In contrast, the
budding yeast UBI4 deletion mutant displays resistance
to cisplatin together with other mutants of the protea-
some pathway including BUL1, UBP13, UFD4 and
UMP1 [43]. Both UBI4 (which has conventionally been
thought to be the major source of Ub for various stress
responses) and DOA1 might supply Ub for the DNA
damage response. Similarly, in fission yeast the corre-
sponding UBI4 homolog gene (S. pombe Ubi4,
SPBC337.08c) may replace Lub1 absence. Accordingly,
Ubi4 gene expression resulted up-regulated by cisplatin
in our previous study, similarly to Lub1 (see Table 4).
As reported in Table 4, the human ortholog of
S. pombe Lub1 and S. cerevisiae DOA1/UFD3, is phos-
pholipase A2 (PLA2)-activating protein (PLAA, also
known as PLAP), that has been implicated in a variety
of biological processes that involve the Ub system [44].
In particular, it has been linked to the maintenance of
Ub levels, but the mechanism by which it accomplishes
this is unclear [44]. Interestingly, it has been recently
demonstrated that human PLAA enhances cisplatin-
induced apoptosis in HeLa cells [45]. Transcriptional
induction of PLAA by cisplatin can potentially promote
cytotoxicity through phospholipase A2 activation and
arachidonic acid accumulation. Interestingly, carbopla-
tin-sensitive cells from ovarian cancer patients expressed
higher levels of PLAA than their resistant counterparts
[46]. The C-terminal domain of PLAA binds p97/Cdc48,
an AAA ATPase which, among other functions, helps in
transferring ubiquitinated proteins to the proteasome
for degradation [44]. In addition, PLAA is also asso-
ciated with HDAC6, a unique cytoplasmic deacetylase
capable of interacting with Ub and a master regulator of
the cell protective response to cytotoxic protein aggre-
gate formation [47,48].
Conclusions
To maintain the genome, cells have evolved multiple
pathways to detect and respond to DNA damage. The
cellular response to DNA damage has been particularly
well characterized in the fission yeast S. pombe.
An important way in which various organisms coordi-
nate facets of the DNA damage response is the
post-translational modification of proteins. While phos-
phorylation has received a great deal of attention, it has
become increasingly clear that other types of post-trans-
lational modifications, such as ubiquitination, also play
critical roles. Ub is an essential modifier conserved in
all eukaryotes from yeast to human and existing in sev-
eral cellular compartments. During normal growth, a
Table 4 Expression profiling studies of fission yeast with
DNA microarrays - S. pombe Functional Genomics Lab
http://www.sanger.ac.uk/PostGenomics/S_pombe/-:
modulation of genes belonging to the ubiquitin-
proteasome pathway
Homolog/Ortholog
Gene name Annotation S. cerevisiae Human
Lub1 Ub proteolysis DOA1/UFD3 PLAA
ubi4 Ub-attachment to target UBI4 UBC
ubc6 Ub ligase UBC6 UBE2J2
SPAC22A12.14c Ub protease - -
Ubx3:mug39 CDC48-dependent degradation UBX3 NSFL1C
Uch2 26S Ub-hydrolase YUH1 UCHL3
Rpn12:mts3 19S regulatory protein RPN12/NIN1 PSMD8
Ubx2:ucp13 CDC48-dependent degradation UBX5 -
Rpn3 19S regulatory protein RPN3/SUN2 PSMD3
SPCC4G3.13c Cue1/4 domain CUE1-4/KIS4 -
a Modulated transcripts are reported for which at least a two-fold up-
regulation was found.
b The S. pombe wild-type sensitive strain 972 (h
-, no auxotrophic markers) was
exposed to a cisplatin concentration inhibiting colony growth by 80% (1.28
mM) after 4h drug exposure.
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proteasomal degradation, and it is presumably seques-
tered within these pathways. However, in the presence
of DNA damage, Ub must be quickly made available for
post-translational modification of proteins involved in
sensing, repairing, and/or tolerating the damage (such as
PCNA and histone H2B). The present study supports
that specific proteasome genes can contribute differently
to cisplatin response. Only a few of yeast genes appear
to regulate sensitivity per se suggesting pathway redun-
dancy. The prospective identification of novel targets for
modulation of cisplatin sensitivity in an eukaryotic
model organism appeared particularly intriguing towards
the discovery of strategies to overcome cisplatin resis-
tance in human tumors. In principle, a variety of
approaches may be employed in an attempt to sensitize
cancer cells to cisplatin (e.g., pharmacological inhibitors,
small interfering RNAs, antisense oligonuclotides). In
the context of the Ub-proteasome pathway, the develop-
ment of small molecules is still at an early stage, but
some research groups are already looking at attacking
components of the Ub-proteasome pathway [49]. In this
regard, the definition of the interactome of the specific
enzymes is crucial to select the most promising drug-
gable targets. Also, a major effort is required to better
understand pathway redundancy because, although ubi-
quitin ligases have shown a high degree of substrate spe-
cificity, their inhibition m a yb ec o u n t e r a c t e db yt h e
activation of alternative pathway components critical for
cell survival maintenance. The level of complexity of the
Ub-proteasome pathway is high as also deubiquitinases
can be regarded as druggable targets (e.g., USP7). More-
over, the pairing of the pathway components with differ-
ent substrates may result in divergent activities [24,25].
In the present study, we identified three Ub-protea-
some mutants exhibiting hypersensitivity to cisplatin,
i.e., Ubp16, Ubc13 and Pmt3. Although with very
distinct functions, the proteins encoded by those genes
play critical roles for DNA damage response, thereby
representing attractive targets to investigate possible
mechanisms of cisplatin resistance in human tumor cell
systems (Figure 2). With respect to factors whose loss
confers cisplatin resistance, Ufd2 might play a role in
cisplatin-induced apoptosis [32,33]. Our screening also
highlighted the importance of the b7 subunit of 20S
proteasome, whose corresponding human ortholog gene
is PSMB4. Since PSMB4 is implicated in proteasomal
degradation of SNEV, the absence of PSMB4 may pro-
duce resistance as a consequence of increased survival
favoured by SNEV [34,35].
To the best of our knowledge, none of the budding
yeast homologues of the fission yeast mutants described
in the present study has been previously linked to cis-
platin response.
When we compared the present screening results with
those obtained in previous global gene expression study,
the importance of Lub1 emerged. Indeed, the corre-
sponding budding yeast ortholog gene (DOA1/UFD3)
has a precise and important role in DNA damage
response and appears to regulate the ubiquitination of
both PCNA and histone H2B, through the interaction
with UBC13 (Ubc13 of S. pombe) and UBP10 (Ubp16 of
S. pombe). PCNA is at the very heart of many essential
cellular processes, such as DNA replication, repair of
DNA damage, chromatin structure maintenance, chro-
mosome segregation and cell-cycle progression. This
puts PCNA in a central position in determining the fate
of replication fork, which ultimately determines both
tumor progression as well as the outcome of anticancer
treatment [50]. In addition, recent advances have
defined a clear role for histone H2B ubiquitination in
transcriptional regulation and the enzymes regulating
DELETION MUTANT LIBRARY
(subset of Ub-proteasome genes)
cisplatin
stress response
cisplatin-sensitive
mutants
ubp16
ubc13
pmt3
cisplatin-resistant
mutants
ufd2
E7 20S
rpt6
DNA damage response
lub1
Figure 2 Summary of the relevant findings of the study.T h e
experimental approach used here and the obtained results are
illustrated to point out the fact that the Ub-proteasome genes
identified in the present study as regulators of cisplatin response are
all implicated in controlling DNA damage response.
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tumorigenesis [51].
In summary, we can conclude that the cell sensitivity
screening shown in the present study, together with evi-
dences resulting from previous S. pombe gene expres-
sion analysis, uncover novel putative targets for
modulation of cisplatin sensitivity, particularly intriguing
towards the discovery of strategies to overcome cisplatin
in human tumors.
Methods
S. pombedeletion library
A genome-wide deletion mutant library was constructed
in large scale by PCR-based targeted mutagenesis at
each target ORF, on the base of the S. pombe genome
sequence information provided by the public website at
The Wellcome Trust Sanger Institute http://www.
sanger.ac.uk. The details of library construction have
been recently reported by Kim et al. [8]. Briefly, the
deletion cassettes were transformed into S. pombe
SP286 diploid host strain (h
+/h
+, ade6-M210/ade6-
M216 ura4-D18/ura4-D18 leu1-32/leu1-32) and deletion
mutants were screened by G418 selection, see also Bio-
neer Schizosaccharomyces pombe http://pombe.bio-
neer.co.kr for details. Non-essential haploid mutants
were obtained from diploid mutants [8]. The library was
provided by the Bioneer Corporation and the Korea
Research Institute of Biotechnology and Bioscience
[8,52]. All viable mutants were screened.
Culture conditions, cytotoxicity assays and drugs
Yeast cultures were grown at 30°C in YE+AUL medium
(5 g of yeast extract, 30 g of glucose, 0.075 g of adenine,
0.075 g of uracil, 0.25 g of leucine and 0.1 g of G418/
liter). A growth inhibition assay performed in microtiter
plates was used to evaluate the antiproliferative effect of
cisplatin (Figure 3). Preliminary experiments were per-
formed to verify the linearity of the relation between
cell number and absorbance at 595 nm. Cell cultures
were grown overnight in liquid medium until mid-log
phase. Eight thousand cells were then seeded in 96-well
microtiter plates and incubated in drug-containing med-
ium. Plates were then incubated for 48 h at 30°C, at
which time the absorbance at 595 nm was measured.
The IC50 was defined as the drug concentration that
reduced the absorbance to 50% of the value measured
for the untreated control culture, and was compared to
cisplatin sensitivity of the corresponding wild-type par-
ental strain (ED 668: h
+ ade6-M216/ura4-D18/leu1-32
or ED 666: h
+ ade6-M210/ura4-D18/leu1-32). In each
experiment, the mean IC50 values obtained for each
strain were divided by the mean IC50 value of the corre-
sponding wild-type parental strain to evaluate the occur-
rence of hypersensitivity or resistance. When the
obtained ratio was < 0.25 the strain was considered
hypersensitive (HS), whereas strains were considered
resistant (R) when the ratio was > 1.5. The 972 h
- strain
and a cisplatin-hypersensitive strain (rad3) [53] were
used in preliminary experiments to optimize the assay.
Each experiment was repeated at least three times using
triplicate wells. Cisplatin (Sigma) was freshly dissolved
in 0.9% NaCl.
List of Abbreviations
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